drugset / Trial / NCT02224937

MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.

NCT02224937

Phase 1 Completed 10 enrolled Zealand University Hospital
RandomizedCrossoverTriple-blindPrevention

Summary

The purpose of this study is to evaluate the percutaneous transportation and pharmacokinetics of melatonincream 12,5% when used on 80% of the body area. A test battery consisting of blood, saliva, urine samples at 1,2,3,4,5,6,7,8,12,24 and 36 hours after cream application. Cognitive parameters are investigated using KSS, FTT and CRT tests at above mentioned time points.

Timeline

Start
2013-12
Primary completion
2014-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 12.5 % Topical